Pathophysiology and treatment of Barrett's esophagus

48Citations
Citations of this article
74Readers
Mendeley users who have this article in their library.

Abstract

Gastroesophageal reflux disease (GERD) affects an estimated 20% of the population in the United States. About 10%-15% of patients with GERD develop Barrett's esophagus, which can progress to adenocarcinoma, currently the most prevalent type of esophageal cancer. The esophagus is normally lined by squamous mucosa, therefore, it is clear that for adenocarcinoma to develop, there must be a sequence of events that result in transformation of the normal squamous mucosa into columnar epithelium. This sequence begins with gastroesophageal reflux, and with continued injury metaplastic columnar epithelium develops. This article reviews the pathophysiology of Barrett's esophagus and implications for its treatment. The effect of medical and surgical therapy of Barrett's esophagus is compared. © 2010 Baishideng.

Cite

CITATION STYLE

APA

Oh, D. S., & de Meester, S. R. (2010). Pathophysiology and treatment of Barrett’s esophagus. World Journal of Gastroenterology, 16(30), 3762–3772. https://doi.org/10.3748/wjg.v16.i30.3762

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free